

NCT02858180 Raw comparison:

Summary:
CHIA has 32 criteria while your personal folder has 39 criteria
Total found criteria: 32/32
Total not Found: 0/32
Total Extra: 7
This trial is VALID



╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╕
│ CHIA Criteria                                     │ Matching Personal Criteria                        │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╡
│ Chronic HCV Infection of Genotype 1 4 5 or 6      │ Chronic HCV Infection of Genotype 1 4 5 or 6      │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ HCV RNA > 103 IU/mL at screening                  │ HCV RNA \> 103 IU/mL at screening                 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ 18 years of age or older                          │ 18 years of age or older                          │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Diagnosis of chronic HCV infection defined as     │ Diagnosis of chronic HCV infection defined as     │
│ positive HCV antibody or HCV RNA more than 6      │ positive HCV antibody or HCV RNA more than 6      │
│ months prior to screening OR an assessment of     │ months prior to screening OR an assessment of     │
│ fibrosis F2 or greater prior to screening         │ fibrosis F2 or greater prior to screening         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ NYHA Class III Subjects with cardiac disease      │ NYHA Class III Subjects with cardiac disease      │
│ resulting in marked limitation of physical        │ resulting in marked limitation of physical        │
│ activity They are comfortable at rest Less than   │ activity They are comfortable at rest Less than   │
│ ordinary physical activity causes fatigue         │ ordinary physical activity causes fatigue         │
│ palpitation dyspnea or anginal pain               │ palpitation dyspnea or anginal pain               │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ NYHA Class IV Patient with cardiac disease        │ NYHA Class IV Patient with cardiac disease        │
│ resulting in inability to carry on any physical   │ resulting in inability to carry on any physical   │
│ activity without discomfort Symptoms of cardiac   │ activity without discomfort Symptoms of cardiac   │
│ insufficiency or of the anginal syndrome may be   │ insufficiency or of the anginal syndrome may be   │
│ present even at rest If any physical activity is  │ present even at rest If any physical activity is  │
│ undertaken discomfort is increased                │ undertaken discomfort is increased                │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ ejection fraction = 30%                           │ ejection fraction ≤ 30%                           │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ hospitalized for heart failure in last 12 months  │ hospitalized for heart failure in last 12 months  │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ ILD criteria diagnosis of interstitial lung       │ ILD criteria diagnosis of interstitial lung       │
│ disease with chronic supplemental oxygen          │ disease with chronic supplemental oxygen          │
│ requirement at rest and/or with exertion          │ requirement at rest and/or with exertion          │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Forced expiratory volume (FEV1)< 30% predicted    │ Forced expiratory volume (FEV1)\< 30% predicted   │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ OR any FEV1 with chronic supplemental oxygen      │ OR any FEV1 with chronic supplemental oxygen      │
│ requirement at rest and/or with exertion          │ requirement at rest and/or with exertion          │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ OR any FEV1 with chronic hypercapnia (baseline    │ OR any FEV1 with chronic hypercapnia (baseline    │
│ partial pressure of arterial carbon dioxide       │ partial pressure of arterial carbon dioxide       │
│ [PaCO2] > 45)                                     │ \[PaCO2\] \> 45)                                  │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Chronic HCV Infection with Genotype 2 or 3        │ Chronic HCV Infection with Genotype 2 or 3        │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Amiodarone Subjects previously treated with       │ Amiodarone Subjects previously treated with       │
│ amiodarone must have stopped the amiodarone at    │ amiodarone must have stopped the amiodarone at    │
│ least 60 days prior to day 1 of SOF/LDV FDC       │ least 60 days prior to day 1 of SOF/LDV FDC       │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Carbamazepine phenytoin phenobarbital             │ Carbamazepine phenytoin phenobarbital             │
│ oxcarbazepine                                     │ oxcarbazepine                                     │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Rifabutin rifampin or rifapentine                 │ Rifabutin rifampin or rifapentine                 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ HIV regimens containing tenofovir or              │ HIV regimens containing tenofovir or              │
│ tipranavir/ritonavir                              │ tipranavir/ritonavir                              │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ St John's wort                                    │ St John's wort                                    │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Rosuvastatin                                      │ Rosuvastatin                                      │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Have any serious or active medical or psychiatric │ Have any serious or active medical or psychiatric │
│ illness which in the opinion of the investigator  │ illness which in the opinion of the investigator  │
│ would interfere with subject treatment assessment │ would interfere with subject treatment assessment │
│ or compliance                                     │ or compliance                                     │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ History of hepatic encephalopathy or variceal     │ History of hepatic encephalopathy or variceal     │
│ hemorrhage                                        │ hemorrhage                                        │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Hepatitis B surface antigen positive              │ Hepatitis B surface antigen positive              │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Hemoglobin (Hb) < 8 g/dL                          │ Hemoglobin (Hb) \< 8 g/dL                         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Platelets = 50 000/mm3                            │ Platelets ≤ 50 000/mm3                            │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ alanine aminotransferase (ALT) aspartase          │ alanine aminotransferase (ALT) aspartase          │
│ aminotransferase (AST) or alkaline phosphatase =  │ aminotransferase (AST) or alkaline phosphatase ≥  │
│ 10 times upper limit of normal(ULN)               │ 10 times upper limit of normal(ULN)               │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Total bilirubin > 3 mg/dl                         │ Total bilirubin \> 3 mg/dl                        │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Severe renal impairment creatinine clearance      │ Severe renal impairment creatinine clearance      │
│ (CrCl) i e < 30 mL/min                            │ (CrCl) i e \< 30 mL/min                           │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ History of major organ transplantation with an    │ History of major organ transplantation with an    │
│ existing functional graft                         │ existing functional graft                         │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ History of clinically-significant drug allergy to │ History of clinically-significant drug allergy to │
│ nucleoside/nucleotide analogs                     │ nucleoside/nucleotide analogs                     │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Pregnant women or women planning to become        │ Pregnant women or women planning to become        │
│ pregnant                                          │ pregnant                                          │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Women who are breastfeeding                       │ Women who are breastfeeding                       │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┤
│ Active or recent history (= 1 year) of drug or    │ Active or recent history (≤ 1 year) of drug or    │
│ alcohol abuse                                     │ alcohol abuse                                     │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╛



Everything was Found



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Abnormal hematological and biochemical parameters including                                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Treatment with any of the following agents                                                          │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ COPD criteria (one of the following)                                                                │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects in the advanced heart failure cohort must meet all HCV criteria and all of the following   │
│ criteria                                                                                            │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ New York Heart Association (NYHA) Class III or IV functional classification                         │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects in the advanced lung disease cohort must have been diagnosed with chronic obstructive      │
│ pulmonary disease (COPD) or interstitial lung disease (ILD) must meet all HCV criteria and meet the │
│ following criteria for COPD or ILD                                                                  │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛